Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population
Abstract
Purpose:
We assessed the performance of the EORTC (European Organisation for Research and Treatment of Cancer) and CUETO (Club Urológico Español de Tratamiento Oncológico) nonmuscle invasive bladder cancer predictive models compared to current United States NCCN Guidelines® in an American population.
Materials and Methods:
We retrospectively analyzed the electronic medical records of patients with nonmuscle invasive bladder cancer in a multicenter population in the United States. We evaluated recurrence-free and progression-free survival according to EORTC and CUETO, and assessed discriminative performance with the c-index at 1 and 5 years. We then compared the discrimination of EORTC and CUETO to the discrimination of the 4 nonmuscle invasive bladder cancer treatment groups described in NCCN Guidelines.
Results:
We identified 1,333 patients with nonmuscle invasive bladder cancer and a median followup of 37 months. At 5 years the recurrence c-index of EORTC and CUETO was 0.59 and 0.56 while for progression it was higher at 0.74 and 0.72, respectively. NCCN Guidelines demonstrated a similar c-index of 0.56 and 0.75, respectively. The discrimination of all 3 risk models decreased in patients who received bacillus Calmette-Guérin. EORTC was better able to identify patients at low risk for recurrence or progression but it overestimated the 5-year risk of progression in patients at high risk. This study was limited by its retrospective design.
Conclusions:
Our work illustrates the need for improved predictive tools for clinicians who treat patients with nonmuscle invasive bladder cancer. However, until new tools are developed NCCN Guidelines are a simple option for clinicians who treat patients with nonmuscle invasive bladder cancer. Those guidelines provide predictive power comparable to that of the EORTC and CUETO models.
References
- 1 NCCN Clinical Practice Guidelines in Oncology—Bladder Cancer, Version 2.2016. Available at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed March 6, 2016. Google Scholar
- 2 : The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics2014; 32: 1093. Google Scholar
- 3 : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 466. Google Scholar
- 4 : Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model. J Urol2009; 182: 2195. Link, Google Scholar
- 5 : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol2017; 71: 447. Google Scholar
- 6 : Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol2008; 53: 992. Google Scholar
- 7 : Bladder cancer. J Natl Compr Canc Netw2013; 11: 446. Google Scholar
- 8 : Concordance for prognostic models with competing risks. Biostatistics2014 Jul 1; 15: 526. Google Scholar
- 9 : What do we mean by validating a prognostic model?. Stat Med2000; 19: 453. Google Scholar
- 10 : Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making2006; 26: 565. Google Scholar
- 11 : Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak2008; 8: 53. Google Scholar
- 12 : Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer2013; 109: 1460. Google Scholar
- 13 : Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. PLoS One2014; 9: e96849. Google Scholar
- 14 : Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology2013; 82: 387. Google Scholar
- 15 : Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guérin therapy. J Urol2005; 174: 2134. Link, Google Scholar
- 16 : Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer2015; 112: 468. Google Scholar
- 17 : EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice?. Clin Genitourin Cancer2016; 14: 176. Google Scholar
- 18 : The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol2011; 60: 423. Google Scholar
- 19 : How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?. Eur Urol2011; 60: 431. Google Scholar
- 20 : The current classification of urothelial neoplasms. Mod Pathol2009; 22: S60. Google Scholar
- 21 : Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int2000; 85: 48. Google Scholar
- 22 : Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol2002; 41: 523. Google Scholar
- 23 : Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int2012; 109: 1666. Google Scholar
- 24 : Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute: risk factors of T1HG-BC. Int J Urol2015; 22: 541. Google Scholar
- 25 : Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models. Korean J Urol2014; 55: 643. Google Scholar
- 26 : EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol2016; 69: 60. Google Scholar
